English
  • Remdesivir

    Remdesivir

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Remdesivir Antiviruls(Ebola, Covid-19) Gilead  

     

    inquirydetail
  • Ruxolitinib

    Ruxolitinib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Ruxolitinib Myelofibrosis Novartis Jul. 6, 2024
    inquirydetail
  • Relugolix

    Relugolix

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Relugolix Prostatic cancer Takeda and ASKA Jan. 24, 2024
    inquirydetail
  • Rimegepant

    Rimegepant

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Rimegepant Migraine headache Biohaven Feb. 22, 2031

     

    inquirydetail
  • Relugolix 737789-87-6

    Relugolix 737789-87-6

    API’s Name Indication Specification US DMF EU DMF CEP
    Ribociclib CAS: 737789-87-6 Antineoplastic In-House      
    inquirydetail
  • Ribociclib 1374639-75-4

    Ribociclib 1374639-75-4

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Ribociclib 1374639-75-4 HR-positive, HER2-negative Andvance ormetastaticbreast Cancers Novartis
    Pharmaceuticals    		 Jun.27, 2028
    inquirydetail
  • Rivaroxaban

    Rivaroxaban

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Rivaroxaban Anticoagulant In-House TDP    
    inquirydetail
  • Rosuvastatin Calcium

    Rosuvastatin Calcium

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Rosuvastatin Calcium Hypercholesterolemia In-House/CEP 20705 √ CEP2015-240
    inquirydetail